Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $36

Benzinga · 5d ago
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $33 to $36.